Epidermal growth factor receptor inhibition induces trichomegaly.
Dueland
Svein
S
Department of Oncology, Ullevaal University Hospital, Oslo, Norway. svein.dueland@labmed.uio.no
Sauer
Torill
T
Lund-Johansen
Fridtjof
F
Ostenstad
Bjørn
B
Tveit
Kjell Magne
KM
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003937:Diagnosis, Differential; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005140:Eyelashes / Q000254:growth & development; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D009362:Neoplasm Metastasis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D066246:ErbB Receptors; D000068818:Cetuximab; D002166:Camptothecin